Cargando…
Neuroimaging of tissue microstructure as a marker of neurodegeneration in the AT(N) framework: defining abnormal neurodegeneration and improving prediction of clinical status
BACKGROUND: Alzheimer’s disease involves accumulating amyloid (A) and tau (T) pathology, and progressive neurodegeneration (N), leading to the development of the AD clinical syndrome. While several markers of N have been proposed, efforts to define normal vs. abnormal neurodegeneration based on neur...
Autores principales: | Gallagher, Rigina L., Koscik, Rebecca Langhough, Moody, Jason F., Vogt, Nicholas M., Adluru, Nagesh, Kecskemeti, Steven R., Van Hulle, Carol A., Chin, Nathaniel A., Asthana, Sanjay, Kollmorgen, Gwendlyn, Suridjan, Ivonne, Carlsson, Cynthia M., Johnson, Sterling C., Dean, Douglas C., Zetterberg, Henrik, Blennow, Kaj, Alexander, Andrew L., Bendlin, Barbara B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583332/ https://www.ncbi.nlm.nih.gov/pubmed/37848950 http://dx.doi.org/10.1186/s13195-023-01281-y |
Ejemplares similares
-
Associations between diffusion MRI microstructure and cerebrospinal fluid markers of Alzheimer's disease pathology and neurodegeneration along the Alzheimer's disease continuum
por: Moody, Jason F., et al.
Publicado: (2022) -
Crosswalk study on blood collection‐tube types for Alzheimer's disease biomarkers
por: Jonaitis, Erin M., et al.
Publicado: (2022) -
Differential effects of neurodegeneration biomarkers on subclinical cognitive decline
por: Merluzzi, Andrew P., et al.
Publicado: (2019) -
Asthma amplifies dementia risk: Evidence from CSF biomarkers and cognitive decline
por: Nair, Ajay Kumar, et al.
Publicado: (2022) -
Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease
por: Erickson, Pontus, et al.
Publicado: (2023)